InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. Our mission is to develop and facilitate market entry for novel products worldwide that preserve and improve vision. To date, we have accomplished this mission with the approval of two DuraSite-based ophthalmologic products:
Our first marketed product, AzaSite® (azithromycin ophthalmic solution) 1%, is approved by the United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis (pink eye). AzaSite is formulated with our DuraSite® technology, which extends the residence time of the antibiotic azithromycin on the eye for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals now a wholly owned division Merck & Co.(NYSE:MRK).
Our second marketed product, Besivance® (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a broad spectrum ocular antibiotic approved by the FDA in May 2009 to treat bacterial conjunctivitis (pink eye). An advantage of Besivance is a faster rate of resolution of the infection that may reduce the duration of the illness and reduce the chances of infecting others. Besivance was developed by Bausch & Lomb and launched in the United States in the second half of 2009.
InSite Vision is continuing on its mission is to develop and facilitate market entry for novel products worldwide that preserve and improve vision with our late-stage (Phase 3) clinical candidates:
AzaSite Plus™ (ISV-502) , is a fixed-dose combination of an antibiotic (1.0% azithromycin) and an anti-inflammatory steroid (0.1% dexamethasone) formulated in DuraSite. AzaSite Plus is currently entering Phase 3 development for the treatment of eyelid infection and inflammation, specifically for the indication of blepharitis.
DexaSite™ (ISV-305), a DuraSite formulation of 0.1% dexamethasone, is also entering Phase 3 development for the treatment of eyelid infection and inflammation, also for the indication of blepharitis.
ISV-303, is a lower dose (0.075%) bromfenac ophthalmic solution formulated in DuraSite, is completing a Phase 2 PK Study head-to-head versus the current market leader - BROMDAY® (Ista Pharmaceuticals), and will soon be entering Phase 3 development for the treatment of inflammation and ocular pain in the post-cataract surgery setting.